← All trials
NCT07076056
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 27, 2022
- Primary completion
- Dec 4, 2023
- Completion date
- Jun 19, 2024
- First posted
- Jul 21, 2025
- Last posted
- Jul 21, 2025
- Enrollment
- 230
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daewon Pharmaceutical Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.